Adjuvant (I-III, A-C) Colon Cancer

Addition of Eloxatin® Following Surgery Delays Cancer Progression in Certain Colorectal Cancers (07-28-2016)

The addition of the chemotherapy combination consisting of Eloxatin (oxalipatin) plus 5-fluorouracil (5 FU) following surgery reduces the risk of cancer progression among patients with deficient mismatch repair (dMMR) stage III colorectal cancer. These... Continue Reading

Stent Placement Reduces Need for Stoma in Some Colorectal Cancers (06-27-2016)

The placement of a stent as initial emergency treatment for colon obstruction reduces the need for a stoma without adversely affecting outcomes for patients with potentially curable colorectal cancer. These results were recently presented at the 2016... Continue Reading

Vectibix® Improves Survival in Colorectal Cancer, Demonstrates Importance of Tissue Testing (01-28-2016)

The addition of Vectibix® (panitumumab) to best supportive care improves survival over best standard care alone among colorectal cancer patients who have stopped responding to chemotherapy. However, the benefit is only seen with patients who have no... Continue Reading

Advances in Genomic Testing-What you Need to Know (09-29-2014)

Q: What is genomic testing? A: Genomic testing looks at a group of genes and their varying levels of expression. This gene expression or activity can characterize how genes interact with one another and predict the behavior of certain tissues within... Continue Reading

Oncotype DX Colon Cancer Test May Reduce Medical Costs Associated with Stage II Disease While Increasing Patient Well-being (09-22-2014)

REDWOOD CITY, Calif., Sept. 12, 2014 /PRNewswire/ – Genomic Health, Inc. (Nasdaq: GHDX) today announced that PharmacoEconomics published positive results from a health economic analysis suggesting that use of the Oncotype® DX colon cancer... Continue Reading

Doctors find that Cholesterol Lowering Statin Drugs may Improve Survival From Colon Cancer (08-26-2014)

According to a new U.K. study, statins, which are widely used cholesterol-lowering drugs, appear to improve colon cancer survival.  The study found that overall, colon cancer patients who took statins such as Lipitor and Zocor had a 29 percent lower... Continue Reading

Study Shows Polypectomy as Effective as Partial Colon Resection (07-2-2014)

A team from Stony Brook University reported that patients requiring removal of colon polyps could be effectively treated with laparoscopic-assisted polypectomy (LACP) and that the procedure required fewer resources than did partial colon resection (laparoscopic... Continue Reading

Genomic Health Announces Results of Oncotype DX(R) Colon Cancer Studies Presented at 2014 American Society of Clinical Oncology Gastrointestinal Cancer (ASCO GI) Symposium (02-7-2014)

New data show real-life impact of Oncotype DX on treatment decisions, underscore clinical validity and utility of the test REDWOOD CITY, Calif., Jan. 29, 2014 /PRNewswire/ — Genomic Health, Inc. (Nasdaq: GHDX) today announced results from the Oncotype... Continue Reading

Oncotype DX Changes Treatment Recommendations in Stage II Colon Cancer (12-26-2013)

Use of the Oncotype DX® colon cancer test changed treatment recommendations in 29 percent of stage II colon cancer patients, according to the results of a study published in Current Medical Research and Opinion. Stage II colon cancer refers to cancer... Continue Reading

Genomic Testing May Reduce Medical Costs for Colon Cancer (06-14-2013)

Use of the Oncotype DX® colon cancer test to guide treatment decisions may reduce medical costs and improve patient well-being. These results were presented at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO). The Oncotype... Continue Reading

Next Page »